Tumor organoids have been used in combination with matching patient peripheral blood lymphocytes to measure the existing cytotoxic activity in response to immuno-oncology drugs as well as to amplify and identify relevant T cell antigen receptors (54–56). The gene discussed is TARP; the disease is neoplasm.